Amela0.01%+4%+0.05%

Amela cream is a fixed-dose triple-combination topical preparation indicated for the short-term treatment (typically up to 8 weeks) of moderate to severe melasma of the face in adults, as an adjunct to a comprehensive skin care and photoprotection program.

Evidence-based classification

• Established/approved use: Short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, used together with broad-spectrum sun protection and a mild cleanser/moisturizer regimen.
• Guideline-supported adjunct use: Often used as part of a stepwise dermatologic melasma treatment plan, sometimes preceded or followed by maintenance with a lower-strength depigmenting regimen once the treatment course is complete.
• Off-label use: Occasionally used off-label for other localized areas of hyperpigmentation (e.g., post-inflammatory hyperpigmentation) under direct physician supervision; this is not an FDA-approved indication and should only be undertaken with medical guidance.

Amela is not intended for continuous long-term or maintenance therapy; treatment is generally limited to a defined course, after which the prescribing physician reassesses the skin.

Fluocinolone Acetonide + Hydroquinone + Tretinoin cream is a fixed combination containing three active ingredients in a single vehicle:

• Fluocinolone Acetonide 0.01% w/w — a mid-potency topical corticosteroid.
• Hydroquinone 4% w/w — a skin-depigmenting (melanin synthesis inhibiting) agent.
• Tretinoin 0.05% w/w — a topical retinoid (vitamin A derivative).

Some marketed formulations also contain sodium metabisulfite as an antioxidant excipient, which is relevant for patients with sulfite hypersensitivity (see Contraindications).

Amela is a dermatologist-prescribed triple-combination cream that brings together a corticosteroid, a depigmenting agent, and a topical retinoid in a single formulation. It is applied once daily to affected areas of the face to reduce the appearance of moderate to severe melasma (patchy facial hyperpigmentation, often related to sun exposure, pregnancy, or hormonal factors).

The three components work together: hydroquinone reduces new pigment (melanin) formation, tretinoin increases epidermal turnover and enhances penetration of the other agents while itself having some depigmenting effect, and fluocinolone acetonide reduces the local skin irritation caused by the other two ingredients and helps dampen inflammatory pigment-stimulating pathways. Because of the corticosteroid component, Amela is intended for short, defined courses of therapy rather than open-ended use.

Amela belongs to the class of combination topical dermatologic preparations, specifically a fixed-dose combination of a topical corticosteroid, a skin-depigmenting agent, and a topical retinoid, used in the management of melasma.

Fluocinolone Acetonide + Hydroquinone + Tretinoin combines three agents with complementary mechanisms of action relevant to hyperpigmentation:

Systemic absorption of all three components through intact skin is generally low with recommended use, but absorption can increase with application to broken or irritated skin, over larger surface areas, or with occlusion.

How to apply Amela:

• Wash the face gently with a mild cleanser and pat dry; wait until the skin is completely dry before application.
• Apply a thin film to the entire affected area of the face (not just individual spots), avoiding the eyes, eyelids, lips, angles of the nose, and mucous membranes.
• Apply approximately 30 minutes before bedtime and wash hands immediately after application.
• Use a moisturizer as needed for dryness, and apply broad-spectrum sunscreen (SPF 30 or higher) every morning and reapply through the day, since all three components increase sun sensitivity.
• Do not apply to eczematous, sunburned, windburned, dry, chapped, or otherwise irritated or broken skin.

Because Amela is applied topically and systemic absorption is limited, clinically significant drug-drug interactions are uncommon. The main concerns are additive local effects with other topical products:

• Other topical irritants or peeling agents (e.g., other retinoids, benzoyl peroxide, alpha-hydroxy or salicylic acid preparations, medicated or abrasive soaps, products with high alcohol content, astringents, lime, spices): concomitant use with Amela can produce additive skin irritation, dryness, and peeling; avoid using these together unless specifically directed by a physician.
• Other topical corticosteroids or depigmenting agents applied to the same area: may increase the risk of skin atrophy, irritation, or uneven depigmentation; avoid combining without medical advice.
• Photosensitizing drugs or products: concurrent use may increase sun sensitivity beyond that already caused by tretinoin and hydroquinone.

The most common adverse effects of Amela are local skin reactions at the application site, generally related to the tretinoin and corticosteroid components:

• Very common: Erythema (redness), burning/stinging sensation, desquamation (peeling), and dryness of treated skin.
• Common: Skin irritation, itching, acneiform eruptions, and mild contact dermatitis.
• Less common but clinically important with prolonged/excessive use: Skin atrophy (thinning), telangiectasia (visible small blood vessels), striae, and rebound hyperpigmentation or exogenous ochronosis (a blue-black skin discoloration) associated with prolonged hydroquinone exposure.
• Uncommon: Hypopigmentation of surrounding normal skin, folliculitis, and allergic contact dermatitis.

Most local reactions are mild to moderate and improve with reduced frequency of application or a brief treatment pause; persistent or severe reactions should be reported to a physician.

Pregnancy: Amela contains tretinoin, a topical retinoid; retinoids as a class are associated with teratogenic risk when given systemically, and although systemic absorption from topical facial use is low, this has not been fully excluded. Amela should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; many prescribers avoid its use entirely during pregnancy. Consult a physician before use if pregnant or planning pregnancy.

Lactation: It is not known whether topically applied fluocinolone acetonide, hydroquinone, or tretinoin (or their metabolites) are excreted in human milk in clinically significant amounts. As a precaution, avoid applying Amela to the chest area, and consult a physician before use while breastfeeding; use only if the potential benefit outweighs the potential risk to the nursing infant.

• Limited duration of use: Amela is intended for short courses (typically up to 8 weeks); prolonged continuous use increases the risk of corticosteroid-related skin atrophy/telangiectasia, and hydroquinone-related rebound hyperpigmentation or exogenous ochronosis. Do not use longer than directed without physician reassessment.
• Photosensitivity: All three components can increase skin sensitivity to sunlight. Use strict sun protection (broad-spectrum sunscreen, protective clothing, minimizing sun exposure) throughout treatment and avoid sunlamps/tanning beds.
• Avoid eyes and mucous membranes: Keep away from the eyes, mouth, angles of the nose, and mucous membranes; if accidental contact occurs, rinse thoroughly with water.
• Not for broken or eczematous skin: Do not apply to sunburned, wind-burned, chapped, abraded, or otherwise damaged or eczematous skin, as absorption and irritation may increase.
• Not for use in children: Not recommended in pediatric patients; safety and efficacy have not been established.
• Systemic corticosteroid effects: Although unlikely with recommended facial use, extensive application, use over prolonged periods, or use under occlusion can theoretically produce systemic corticosteroid absorption; discontinue and consult a physician if signs of systemic effects occur.
• External use only: For topical dermatologic use only; not for oral, ophthalmic, intravaginal, or intranasal use.
• Flammability: Some formulations may be flammable; keep away from open flame.

Excessive or too-frequent topical application of Amela does not speed improvement and instead increases the likelihood of marked local irritation, redness, and peeling; if this occurs, reduce frequency of use or pause treatment and consult a physician.

If Amela cream is accidentally ingested, or if a severe allergic reaction or significant systemic symptoms occur, seek immediate medical attention or contact a poison control center/emergency services right away; do not attempt specific home treatment for ingestion or significant systemic exposure.

Store at room temperature (below 30°C), away from light and moisture. Keep the tube tightly closed after use. Keep out of reach of children.

• Elderly: No specific dose adjustment is established; use with the same precautions as in other adults, monitoring for skin fragility.
• Renal/hepatic impairment: Systemic absorption from topical facial application is minimal, and no formal dose adjustment has been established; use with routine caution.
• Dark or sensitive skin types: Use with caution and physician guidance, as depigmenting therapy can occasionally cause uneven pigmentation; discontinue if irritation or unexpected pigment changes occur.
• Pediatric patients: See Pediatric Use.
• Pregnancy and lactation: See Pregnancy and Lactation.

Amela is typically used for a defined course of up to 8 weeks. If no improvement in melasma is seen after 8 weeks of treatment, or if the condition worsens, the prescribing physician should reassess the diagnosis and treatment plan. Continuous use beyond 8 weeks is not routinely recommended and should only occur under direct physician supervision, given the risks of corticosteroid-related skin atrophy and hydroquinone-related pigmentary complications with prolonged exposure.

Fluocinolone Acetonide + Hydroquinone + Tretinoin is a fixed-dose combination spanning three drug classes: a topical corticosteroid (fluocinolone acetonide), a skin-depigmenting agent/tyrosinase inhibitor (hydroquinone), and a topical retinoid (tretinoin), combined for the management of melasma.

Fluocinolone Acetonide + Hydroquinone + Tretinoin works through the complementary actions of its three components: hydroquinone inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis, reducing new pigment production; tretinoin accelerates epidermal cell turnover, promoting shedding of pigmented cells and enhancing penetration of hydroquinone; and fluocinolone acetonide, a mid-potency corticosteroid, reduces the local inflammation and irritation that tretinoin and hydroquinone can otherwise cause, while also helping to limit inflammation-driven pigment stimulation. Together, these mechanisms produce a greater lightening effect on melasma than any single agent used alone.

C

The safety and efficacy of Amela have not been established in pediatric patients. It is not recommended for use in children or adolescents. Use in this population should only be considered by a physician in exceptional circumstances, with careful weighing of risks and benefits.